



## Dysport® (abobotulinumtoxinA)

When requesting Dysport® (abobotulinumtoxinA), the individual requiring treatment must be diagnosed with one of the following approved indications and meet the specific coverage guidelines and applicable safety criteria for the covered indications.

### FDA-approved Indications

- Cervical dystonia
- Upper and lower limb spasticity in patients 2 years of age and older

### Approved Off-label Compensial Uses

- Blepharospasm
- Hemifacial spasm
- Anal fissure
- Chronic sialorrhea

### Coverage Guidelines

Approval duration of 12 months will be granted for the following indications:

- Cervical dystonia
- Upper and lower limb spasticity
- Blepharospasm
- Hemifacial spasm
- Anal fissure
- Chronic sialorrhea

### Dosing Recommendations

#### Cervical Dystonia

Approve up to a maximum dose of 1,000 units, administered intramuscularly not more frequently than once every 12 weeks.

#### Adult Upper Limb Spasticity

Approve up to a maximum dose of 1,000 units, administered intramuscularly not more frequently than once every 12 weeks. Maximum volume is 1mL per injection site.

#### Adult Lower Limb Spasticity

Approve up to a maximum dose of 1,500 units, administered intramuscularly not more frequently than once every 12 weeks. Maximum volume is 1mL per injection site.

**Pediatric Upper Limb Spasticity**

Approve up to a maximum dose of 16 units/kg (not to exceed 640 units), administered intramuscularly not more frequently than once every 12 weeks.

**Pediatric Lower Limb Spasticity**

Approve up to 15 units/kg for unilateral lower limb injections or 30 units/kg for bilateral lower limb injections, or 1,000 units (whichever is lower), administered intramuscularly not more frequently than once every 12 weeks.

**Blepharospasm**

Approve up to a maximum dose of 120 units, administered subcutaneously not more frequently than once every 12 weeks.

**Hemifacial Spasm**

Approve up to a maximum dose of 220 units, administered subcutaneously not more frequently than once every 3 months.

**Anal Fissure**

Approve up to a maximum dose of 1,200 units, administered not more frequently than once every 3 months.

**Chronic Sialorrhea**

Approve up to a maximum dose of 300 units (150 units per side), administered not more frequently than once every 16 weeks.

## References

1. Dysport® for injection [prescribing information]. Cambridge, MA and Fort Worth, TX: Ipsen/Galderma; July 2020.
2. Smith CP, Chancellor MB. Emerging role of botulinum toxin in the management of voiding dysfunction. *J Urol*. 2004;17(6 Pt 1):2128-2137.
3. Brisinda G, Bentivoglio AR, Maria G, et al. Treatment with botulinum neurotoxin of gastrointestinal smooth muscles and sphincters spasms. *Mov Disord*. 2004;19(Suppl 8):S146-S156.
4. Wald A, Bharucha AE, Cosman BC, et al. ACG clinical guideline: management of benign anorectal disorders. *Am J Gastroenterol*. 2014;109(8):1141-57. Available at: <http://gi.org/guideline/management-of-benign-anorectal-disorders/>. Accessed on May 27, 2020.
5. Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins: A review, part 2. *Am J Health Syst Pharm*. 2006;63(3):225-232.
6. Truong D, Comella C, Fernandez HH, et al.; Dysport Benign Essential Blepharospasm Study Group. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: a randomized, placebo-controlled, phase II trial. *Parkinsonism Relat Disord*. 2008;14(5):407-14.
7. Kollewe K, Mohammadi B, Köhler S, et al. Blepharospasm: long-term treatment with either Botox®, Xeomin® or Dysport®. *J Neural Transm*. 2015;122(3):427-31.
8. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2016;86:1818-1826. Available at: <http://www.neurology.org/content/86/19/1818.full>. Accessed on May 27, 2020.
9. Naumann M, So Y, Argoff AE, et al. Assessment: botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. *Neurology*. 2008;70:1707-1714. Available at: <http://neurology.org/content/70/19/1707.full>. Accessed on May 29, 2020.
10. Bhidayasiri R, Truong DD. Expanding use of botulinum toxin. *J Neurol Sci*. 2005;235(1-2):1-9.
11. Tan EK. Botulinum toxin treatment of sialorrhea: comparing different therapeutic preparations. *Eur J Neurol*. 2006;13 (Suppl 1):60-64.
12. Sheffield JK, Jakovic J. Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease. *Expert Rev Neurotherapeutics*. 2007;7(6):637-647.
13. Pathak MS, Nguyen HT, Graham HK, et al. Management of spasticity in adults: practical application of botulinum toxin. *Eur J Neurol*. 2006;13 Suppl 1:42-50.
14. Bakheit AM, Pittock S, Moore AP, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. *Eur J Neuro*. 2001;8:559-565.
15. Ubhi T, Bhakta BB, Ives HL, et al. Randomised double-blind placebo-controlled trial of the effect of botulinum toxin on walking in cerebral palsy. *Arch Dis Childhood*. 2000;83:481-487.
16. Park ES, Rha DW. Botulinum toxin type A injection for management of upper limb spasticity in children with cerebral palsy: a literature review. *Yonsei Med J*. 2006;47(5):589-603.
17. Frei K, Truong DD, Dressler D. Botulinum toxin therapy of hemifacial spasm: comparing different therapeutic preparations. *Eur J Neurol*. 2006;13(Suppl 1):30-35.
18. Kollewe K, Mohammadi B, Dengler R, et al. Hemifacial spasm and reinnervation synkinesias: long-term treatment with either Botox or Dysport. *J Neural Transm*. 2010;117:759-763.
19. Stewart DB Sr, Gaertner W, Glasgow S, Migaly J, Feingold D, Steele SR. Clinical practice guideline for the management of anal fissures. *Dis Colon Rectum*. 2017;60(1):7-14.
20. Vashishta R, Nguyen SA, White DR, Gillespie MB. Botulinum toxin for the treatment of sialorrhea: a meta-analysis. *Otolaryngol Head Neck Surg*. 2013;148(2):191-196.
21. AbobotulinumtoxinA (Dysport®). Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Updated; December 13, 2020; Accessed June 2, 2021.